Figure 3.

Adjusted CKD stages 3–5 prevalence in the population aged 45–74 years, in IDMS studies. Prevalence was age- and sex-adjusted to the EU27 population of 2005. The study names in uncolored regions are studies which used non–IDMS-standardized creatinine or studies which recruited subjects aged ≥50 years; the CKD prevalence results of these studies are shown in Supplemental Appendix 1. 3C, Three City Study; ActiFE, Activity and Function in the Elderly in Ulm study; EPIRCE, Estudio Epidemiológico de la Insuficiencia Renal en España; ESTHER, Epidemiologische Studie zu Chancen der Verhütung, Früherkennung und optimierten THerapie chronische ERkrankungen in der älteren Bevolkerung; FINRISK, Finland Cardiovascular Risk Study; HUNT, Nord-Trøndelag Health Study; INCIPE, Initiative on Nephropathy, of relevance to public health, which is Chronic, possibly in its Initial stages, and carries a Potential risk of major clinical Endpoints; LifeLines, LifeLines Cohort and Study Biobank; MATISS, Malattie cardiovascolari ATerosclerotiche Istituto Superiore di Sanita; MONA LISA, MOnitoring NAtionaL du rISque Arterie; MRC, Medical Research Council trial of assessment and management of older people in the community; PIVUS, Prospective Investigation of the Vasculature in Uppsala Seniors Study; PolSenior, Medical, psychological, sociological and economical aspects of aging of people in Poland; PREVADIAB, Prevalence of Diabetes and Risk Factors in Portugal; PREVEND, Prevention of Renal and Vascular End-stage Disease; SLAN, Survey of Lifestyle and Attitudes & Nutrition in Ireland; VIP, Valle dell'Irno Prevenzione